It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment strategies in the real-world practice and to estimate the outcomes of patients treated with second-line targeted therapy for metastatic renal cell carcinoma (mRCC).
Nội dung trích xuất từ tài liệu:
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: Data from a national registry
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: Data from a national registry
Số trang: 8
Loại file: pdf
Dung lượng: 381.84 KB
Lượt xem: 15
Lượt tải: 0
Thông tin tài liệu:
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Renal cell carcinoma Vascular endothelial growth factor Progression-free survival Overall survivalTài liệu có liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 179 0 0 -
6 trang 171 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 150 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 135 0 0 -
12 trang 103 0 0
-
19 trang 81 0 0
-
17 trang 71 0 0
-
9 trang 48 0 0
-
9 trang 43 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 43 0 0
